The Reliability of the Physical Performance Test in the Clinical Setting for Patients with End Stage Lung Disease and Lung Transplant Recipients

1996 ◽  
Vol 7 (4) ◽  
pp. 9-11 ◽  
Author(s):  
C L Wells ◽  
S L Whitney
Keyword(s):  
Lung Disease ◽  
Physical Performance ◽  
Clinical Setting ◽  
Lung Transplant ◽  
Performance Test ◽  
Transplant Recipients ◽  
Physical Performance Test ◽  
Lung Transplant Recipients ◽  
End Stage

scholarly journals Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma

Rheumatology ◽  
2019 ◽  
Vol 59 (4) ◽  
pp. 790-798
Author(s):  
Alicia M Hinze ◽  
Cheng T Lin ◽  
Amira F Hussien ◽  
Jamie Perin ◽  
Aida Venado ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Longitudinal Assessment ◽  
Hounsfield Units ◽  
Lung Density ◽  
Native Lung ◽  
Single Lung Transplant ◽  
Lung Transplant Recipients

Abstract Objective To investigate the natural history of fibrotic lung disease in recipients of a single lung transplant for scleroderma-associated interstitial lung disease (ILD). Methods Global ILD (including ground glass, nodular opacities and fibrosis) was categorized into severity quintiles on first and last post-transplant CT scans, and percent fibrosis by manual contouring was also determined, in nine single lung transplant recipients. Quantitative mean lung densities and volumes for the native and allograft lungs were also acquired. Results In the native lung, global ILD severity quintile worsened in two cases and percent fibrosis worsened in four cases (range 5–28%). In the lung allograft, one case each developed mild, moderate and severe ILD; of these, new fibrotic ILD (involving <10% of lung) occurred in two cases and acute cellular rejection occurred in one. The average change in native lung density over time was +2.2 Hounsfield Units per year and lung volume +1.4 ml per year, whereas the allograft lung density changed by –5.5 Hounsfield Units per year and total volume +27 ml per year (P = 0.011 and P = 0.039 for native vs allograft density and volume comparisons, respectively). Conclusions While the course of ILD in the native and transplanted lungs varied in this series, these cases illustrate that disease progression is common in the native lung, suggesting that either the immune process continues to target autoantigens or ongoing fibrotic pathways are active in the native lung. Mild lung disease may occur in the allograft after several years due to either allograft rejection or recurrent mild ILD.

Pediatric Recipients of Living Donor Lobar Lung Transplants: Postoperative Care

2002 ◽  
Vol 12 (2) ◽  
pp. 81-85 ◽  
Author(s):  
Monica V. Horn ◽  
Felicia A. Schenkel ◽  
Marlyn S. Woo ◽  
Vaughn A. Starnes
Keyword(s):  
Postoperative Care ◽  
Living Donor ◽  
Lung Transplant ◽  
Fluid Management ◽  
Transplant Recipients ◽  
Intraoperative Management ◽  
Lung Transplants ◽  
Tube Suction ◽  
Lung Transplant Recipients ◽  
End Stage

Bilateral living donor lobar lung transplantation is a treatment option for selected children and adults with end-stage lung disease. Careful donor evaluation, skilled intraoperative management and surgical technique, and diligent immediate postoperative care and follow-up all contribute to better outcomes. Although medical management of whole lung transplant recipients in the immediate postoperative period is similar to that of lobar lung transplant recipients, there are specific differences. Anatomical distinctions, such as the entire cardiac output flowing to 2 lobes instead of 5, and thoracic space issues with simultaneous mechanical ventilation and chest tube suction, contribute to these differences. Early postoperative care, including initial postoperative stabilization, ventilation, fluid management, rejection/infection surveillance and prophylaxis, and beginning rehabilitation, can be adapted to ensure successful outcomes in these patients.

scholarly journals Optimizing Nutrition Assessment to Create Better Outcomes in Lung Transplant Recipients: A Review of Current Practices

Nutrients ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 2884
Author(s):  
Mara Weber Gulling ◽  
Monica Schaefer ◽  
Laura Bishop-Simo ◽  
Brian C. Keller
Keyword(s):  
Body Composition ◽  
Lung Transplantation ◽  
Body Mass ◽  
Lung Transplant ◽  
Assessment Tools ◽  
Transplant Recipients ◽  
Body Composition Assessment ◽  
Lung Transplant Recipients ◽  
End Stage

Lung transplantation offers patients with end-stage lung disease an opportunity for a better quality of life, but with limited organ availability it is paramount that selected patients have the best opportunity for successful outcomes. Nutrition plays a central role in post-surgical outcomes and, historically, body mass index (BMI) has been used as the de facto method of assessing a lung transplant candidate’s nutritional status. Here, we review the historical origins of BMI in lung transplantation, summarize the current BMI literature, and review studies of alternative/complementary body composition assessment tools, including lean psoas area, creatinine-height index, leptin, and dual x-ray absorptiometry. These body composition measures quantify lean body mass versus fat mass and may provide a more comprehensive analysis of a patient’s nutritional state than BMI alone.

scholarly journals COPA SYNDROME-ASSOCIATED MUTATIONS IN LUNG TRANSPLANT RECIPIENTS FOR INTERSTITIAL LUNG DISEASE

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A1265-A1266
Author(s):  
Sarah Beshay ◽  
Jessica Smith ◽  
Isabella Osuna ◽  
Justin Branch ◽  
Laura Muruato ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Lung Transplant Recipients ◽  
Copa Syndrome

scholarly journals Optimizing Nutrition Assessment to Create Better Outcomes in Lung Transplant Recipients: A Review of Current Practices

2019 ◽  
Author(s):  
Mara Weber Gulling ◽  
Monica Schaefer ◽  
Laura Bishop-Simo ◽  
Brian C. Keller
Keyword(s):  
Body Composition ◽  
Lung Transplantation ◽  
Body Mass ◽  
Lung Transplant ◽  
Assessment Tools ◽  
Transplant Recipients ◽  
Body Composition Assessment ◽  
Lung Transplant Recipients ◽  
End Stage

Lung transplantation offers patients with end stage lung disease an opportunity for a better quality of life, but with limited organ availability it is paramount that selected patients have the best opportunity for successful outcomes. Nutrition plays a central role in post-surgical outcomes and historically, body mass index (BMI) has been used as the de facto method of assessing a lung transplant candidate’s nutritional status. Here we review the historical origins of BMI in lung transplantation, summarize the current BMI literature, and review studies of alternative/complementary body composition assessment tools, including lean psoas area, creatinine-height index, leptin, and dual x-ray absorptometry. These body composition measures quantify lean body mass versus fat mass and may provide a more comprehensive analysis of a patient’s nutritional state than BMI alone.

scholarly journals Mycobacteria: Selection of Transplant Candidates and Post–lung Transplant Outcomes

2021 ◽  
Vol 42 (03) ◽  
pp. 460-470
Author(s):  
Daniel Z.P. Friedman ◽  
Karen Doucette
Keyword(s):  
Lung Transplant ◽  
Clinical Presentation ◽  
Nontuberculous Mycobacteria ◽  
Transplant Recipients ◽  
The Past ◽  
Lung Transplants ◽  
Transplant Candidates ◽  
Lung Transplant Recipients ◽  
End Stage ◽  
Selection Of

Abstract Mycobacterium is a large, clinically relevant bacterial genus made up of the agents of tuberculosis and leprosy and hundreds of species of saprophytic nontuberculous mycobacteria (NTM). Pathogenicity, clinical presentation, epidemiology, and antimicrobial susceptibilities are exceptionally diverse between species. Patients with end-stage lung disease and recipients of lung transplants are at a higher risk of developing NTM colonization and disease and of severe manifestations and outcomes of tuberculosis. Data from the past three decades have increased our knowledge of these infections in lung transplant recipients. Still, there are knowledge gaps to be addressed to further our understanding of risk factors and optimal treatments for mycobacterial infections in this population.

Airway complications in lung transplant recipients with telomere‐related interstitial lung disease

2021 ◽  
Author(s):  
Bina Choi ◽  
Jonathan Messika ◽  
Andrew Courtwright ◽  
Jean François Mornex ◽  
Sandrine Hirschi ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Airway Complications ◽  
Lung Transplant Recipients

Critical Care of Heart-Lung and Lung Transplant Recipients

2019 ◽  
pp. 446-452
Author(s):  
Ramachandra R. Sista
Keyword(s):  
Critical Care ◽  
Lung Transplant ◽  
Survival Rates ◽  
Transplant Recipients ◽  
Successful Therapy ◽  
Heart Lung Transplant ◽  
The Past ◽  
Complex Procedure ◽  
Lung Transplant Recipients ◽  
End Stage

Lung transplant is a complex procedure that has been a successful therapy for various end-stage lung diseases since the 1980s. Combined heart-lung transplant, however, is performed much less frequently than in the past. Survival rates after lung transplant have been stable over the past several years (90% survival at 3 months, 80% at 1 year, 60% at 3 years, and 45% at 5 years). The types of transplant procedures available and the general indications for lung transplant are listed in this chapter.

Sign in / Sign up

Export Citation Format

Share Document